Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
  • Patent number: 11312709
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: April 26, 2022
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Anish Bandyopadhyay, Mui Cheung, Hilary Schenck Eidam, Hemant Joshi, Dai-Shi Su
  • Publication number: 20220119417
    Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 6, 2021
    Publication date: April 21, 2022
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Patent number: 11274102
    Abstract: The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: March 15, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David Favre, Robert G. Ferris, Jun Tang
  • Patent number: 11253499
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 22, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Geoffroy Dequirez, Nicolas Willand
  • Patent number: 11254671
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Gianpaolo Bravi, Heather Hobbs, Graham George Adam Inglis, Simon Nicolle, Simon Peace
  • Patent number: 11254689
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 22, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Nicolas Willand
  • Patent number: 11253500
    Abstract: The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David Barros Aguirre, Robert H. Bates, Ruben Gonzalez Del Rio, Alfonso Mendoza Losana, Santiago Ramón García
  • Publication number: 20220023409
    Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 27, 2022
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Catherine COHET, Jeanne-Marie Josephine DEVASTER, David MAYHEW, Bruce MILLER, Ruth TAL-SINGER, Vincent WEYNANTS, Thomas WILKINSON
  • Patent number: 11203632
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: December 21, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Publication number: 20210387988
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.
    Type: Application
    Filed: January 15, 2019
    Publication date: December 16, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Nicholas Paul BARTON, Sophie Marie BERTRAND, Kenneth David DOWN, Matthew GRAY
  • Patent number: 11197857
    Abstract: The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: December 14, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Olena I. Barbash, Andy Fedoriw, Sarah Gerhart, Ryan G. Kruger, Jenny Laraio, Helai Mohammad, Shane W. Obrien, Jacob Rubin, Niyant Shah, Ping Zhang
  • Publication number: 20210362898
    Abstract: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilize
    Type: Application
    Filed: December 11, 2018
    Publication date: November 25, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventor: Francesco SANMARTIN
  • Publication number: 20210361772
    Abstract: Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid, leads to accumulation of the carboxylic acid hydrolysis product in the cell and enables improved or more prolonged enzyme or receptor modulation relative to the unconjugated modulator.
    Type: Application
    Filed: May 21, 2021
    Publication date: November 25, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Alan Hornsby DAVIDSON, Alan Hastings DRUMMOND, Lindsey Ann NEEDHAM
  • Patent number: 11167022
    Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 9, 2021
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Catherine Cohet, Jeanne-Marie Josephine Devaster, David Mayhew, Bruce Miller, Ruth Tal-Singer, Vincent Weynants, Thomas Wilkinson
  • Patent number: 11130811
    Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO: 1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 28, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Yao-Bin Liu, Patrick Mayes, Radha Shah Parmar
  • Patent number: 11119158
    Abstract: An electronic device including a continuity sensor and electrical circuitry configured to detect and report the continuity state of an article, container or product packaging is disclosed. The continuity sensor includes a first substrate with first and second coils thereon, and a second substrate with a third coil thereon. The first coil has an integrated circuit electrically connected thereto. The first substrate is part of, or is attached or secured to a part of the article, container or packaging. The second substrate is another part of, or is attached or secured to another part of the article, container or packaging. One of the article, container or packaging parts is (re)movable with respect to the other part. The first and second coils have one coupling when the article, container or packaging is closed or sealed, and a different coupling when the article, container or packaging is open or unsealed.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 14, 2021
    Assignees: Thin Film Electronics ASA, GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Somnath Mukherjee, James Godfrey
  • Patent number: 11117905
    Abstract: The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 14, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: James Francis Callahan, Roderick S. Davis, Nicole Cathleen Goodwin, Jeffrey K. Kerns
  • Patent number: 11111262
    Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: September 7, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Fimbrion Therapeutics, Inc.
    Inventors: Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
  • Patent number: 11098312
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 24, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Robyn Alexandra Emmins, Gary Brian Finka, Michael Hoare, Alan Peter Lewis, William John Kenneth Lewis, Adam Daniel McInally, Mark Uden, Ioannis Voulgaris
  • Publication number: 20210238172
    Abstract: The invention relates to combinations comprising a compound of the formula: or a salt thereof; and one or more additional pharmaceutically agents active against HIV, and methods of using the same.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 5, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth CHARNLEY, Michael Gerard DARCY, Jason W. DODSON, Xiaoyang DONG, David FAVRE, Terry Vincent HUGHES, Jianxing KANG, Lara Kathryn LEISTER, Yuehu LI, Yiqian LIAN, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG